---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-036988"
form_type: "8-K"
ticker: "AMLX"
cik: "0001658551"
company_name: "Amylyx Pharmaceuticals, Inc."
filed_at: "2023-02-14T23:59:59+00:00"
generated_at: "2026-06-19T14:01:42.751318+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Amylyx expects Q4 and FY 2022 revenue to meaningfully exceed consensus on higher RELYVRIO demand

## Summary
- Insurers covering ~25% of U.S. covered lives have published policies; nearly all provide broad access to RELYVRIO.
- EU decision on AMX0035 marketing authorization for ALS expected first half 2023; CHMP SAG meeting this month.
- Phase 3 PHOENIX trial (664 participants) completed enrollment; topline results anticipated mid-2024.
- Starting Feb 19, pharmacy network data will no longer flow to third-party data vendors (closed network model).
- Company provides update at SVB Securities conference; Q4 and FY 2022 financial results call in early March 2023.

## SEC filing metadata
- accession: 0001193125-23-036988
- form_type: 8-K
- ticker: AMLX
- cik: 0001658551
- company_name: Amylyx Pharmaceuticals, Inc.
- filed_at: 2023-02-14T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/0001193125-23-036988-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658551/000119312523036988/d461886d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-036988
- JSON: https://secwatch.observer/filing/0001193125-23-036988.json
- Plain text: https://secwatch.observer/filing/0001193125-23-036988.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.